Main content area

HSP90 regulates cell survival via inositol hexakisphosphate kinase-2

Chakraborty, Anutosh, Koldobskiy, Michael A., Sixt, Katherine M., Juluri, Krishna R., Mustafa, Asif K., Snowman, Adele M., van Rossum, Damian B., Patterson, Randen L., Snyder, Solomon H.
Proceedings of the National Academy of Sciences of the United States of America 2008 v.105 no.4 pp. 1134-1139
antineoplastic agents, apoptosis, catalytic activity, cell viability, drug therapy, enzymes, heat shock proteins, inositols, mutation, neoplasm cells, neoplasms
Heat-shock proteins (HSPs) are abundant, inducible proteins best known for their ability to maintain the conformation of proteins and to refold damaged proteins. Some HSPs, especially HSP90, can be antiapoptotic and the targets of anticancer drugs. Inositol hexakisphosphate kinase-2 (IP6K2), one of a family of enzymes generating the inositol pyrophosphate IP7 [diphosphoinositol pentakisphosphate (5-PP-IP5)], mediates apoptosis. Increased IP6K2 activity sensitizes cancer cells to stressors, whereas its depletion blocks cell death. We now show that HSP90 physiologically binds IP6K2 and inhibits its catalytic activity. Drugs and selective mutations that abolish HSP90-IP6K2 binding elicit activation of IP6K2, leading to cell death. Thus, the prosurvival actions of HSP90 reflect the inhibition of IP6K2, suggesting that selectively blocking this interaction could provide effective and safer modes of chemotherapy.